Equity (Tables)
|
12 Months Ended |
Mar. 31, 2026 |
| Equity [Abstract] |
|
| Schedule of Common Stock Reserved for Issuance |
The Company has shares of common stock reserved for issuance as follows (in thousands): | | | | | | | | | March 31, 2026 | | | | | | | | Common stock warrants | 194 | | | | | 2010 Plan | | | | | Options outstanding | 7,896 | | | | | | | | 2021 Plan | | | | Awards outstanding | 5,925 | | | | | Shares available for future grant | 41,616 | | | | | 2021 ESPP | 11,500 | | | | | Options outstanding outside the Plans | 2,568 | | | | | Total | 69,699 | | | |
|
| Schedule of Stock Option Activity |
Stock option activities within the Plans as well as outside of the Plans were as follows: | | | | | | | | | | | | | | | | | | | | | | | | | Number of Shares (in thousands) | | Weighted-Average Exercise Price | | Average Remaining Contractual Term (in years) | | Aggregate Intrinsic Value (in thousands) | | Balance, March 31, 2025 | 13,013 | | | $ | 4.82 | | | 4.92 | | $ | 692,422 | | | | | | | | | | | Options exercised | (2,399) | | | 3.63 | | | | | | | Options forfeited or expired | (150) | | | 7.06 | | | | | | | Balance, March 31, 2026 | 10,464 | | | 5.06 | | | 3.97 | | 190,827 | | | Vested and exercisable as of March 31, 2026 | 9,133 | | | 4.63 | | | 3.84 | | 170,507 | | | Vested and expected to vest as of March 31, 2026 | 10,464 | | | 5.06 | | | 3.97 | | 190,827 | |
|
| Schedule of Restricted Stock Unit Activity |
The following table summarizes RSU activity (in thousands, except per share information): | | | | | | | | | | | | | Number of Shares | | Weighted- Average Grant Date Fair Value | | Unvested balance, March 31, 2025 | 3,347 | | | $ | 31.66 | | | Granted | 2,318 | | | 52.92 | | | Vested | (2,001) | | | 37.04 | | | Forfeited | (323) | | | 37.24 | | | Unvested balance, March 31, 2026 | 3,341 | | | 42.65 | |
|
| Schedule of Performance Based Units Activity |
The following table summarizes PSU activity (in thousands, except per share information): | | | | | | | | | | | | | Number of Shares | | Weighted- Average Grant Date Fair Value | | Unvested balance, March 31, 2025 | 480 | | | $ | 40.28 | | | Granted | 2,648 | | | 33.50 | | | Vested | (482) | | | 25.52 | | | Forfeited | (62) | | | 33.77 | | | Unvested balance, March 31, 2026 | 2,584 | | | 36.24 | |
|
| Schedule of Stock-Based Compensation Expense |
Total stock-based compensation expense recognized in the consolidated statement of operations was as follows (in thousands): | | | | | | | | | | | | | | | | | | | Fiscal Year Ended March 31, | | 2026 | | 2025 | | 2024 | | Cost of revenue | $ | 11,680 | | | $ | 11,001 | | | $ | 9,479 | | | Research and development | 46,159 | | | 19,394 | | | 11,978 | | | Sales and marketing | 39,397 | | | 26,323 | | | 16,857 | | | General and administrative | 24,391 | | | 15,668 | | | 9,116 | | Restructuring | — | | | — | | | 3,646 | | | Total stock-based compensation expense | $ | 121,627 | | | $ | 72,386 | | | $ | 51,076 | |
|